|
|
Related Pages |
|
|
|
Breast Cancer Home Page
NCI's gateway for information about breast cancer.
U.S. Task Force: Chemoprevention of Breast Cancer
The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer.
Estrogen Receptors, Tamoxifen, and Raloxifene
Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).
|
|
|
|
|
|
STAR Background
The following links will take you to press releases and other materials concerning the STAR trial that have been prepared by the National Cancer Institute's Office of Communications and Education.
Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer
(Posted: 04/17/2006, Updated: 06/21/2006) - Results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. Questions and Answers, STAR en Español
STAR Results: Raloxifene as Effective as Tamoxifen, Better Safety Profile
An article from the April 18, 2006, issue of the NCI Cancer Bulletin.
Major Breast Cancer Prevention Study Enters Final Stretch
An article from the March 9, 2004, issue of the NCI Cancer Bulletin.
Difusión de resultados iniciales del Estudio del Tamoxifeno y del Raloxifeno (STAR): el fármaco para el tratamiento de la osteoporosis, raloxifeno, es tan efectivo como el Tamoxifeno en la prevención de cáncer de seno invasor
(Publicación: 04/17/2006) - Los resultados iniciales del Estudio del Tamoxifeno y del Raloxifeno, STAR, demuestran que el fármaco raloxifeno, actualmente utilizado para prevenir y tratar la osteoporosis en mujeres posmenopáusicas, funciona tan bien como el tamoxifeno para reducir el riesgo de cáncer de seno entre las mujeres posmenopáusicas que tienen riesgo elevado de padecer la enfermedad. Preguntas y respuestas
Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene)
Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene) montrent
que le raloxifène, habituellement utilisé dans la prévention et le traitement de
l'ostéoporose chez la femme ménopausée, est aussi efficace que le tamoxifène à réduire
le risque de cancer du sein chez la femme ménopausée déjà à risque.
< Previous Section | Next Section > |